Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD partners with AtomVie to develop B7H3 trial doses

Wednesday, October 16, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced a partnership with AtomVie to develop doses for the B7H3 trial. This collaboration aims to enhance the therapeutic potential of their candidate, Betabart (RV-01). The partnership is expected to accelerate the clinical development process, following recent positive updates from Radiopharm's various programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD partners with AtomVie to advance B7H3 trial doses.
  • The collaboration may enhance the development of innovative therapies.
  • Positive clinical updates across multiple programs indicate progress.

Full Press Release Details

• Announcements
• October 16, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• January 10, 2022
• Announcements
• November 25, 2024
• Announcements
• March 6, 2024
• Announcements
• December 10, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of RAD's partnership with AtomVie?

The partnership focuses on developing doses for the B7H3 trial.

What is the candidate being developed in this trial?

The candidate being developed is Betabart (RV-01).

What recent updates have been shared by Radiopharm?

Radiopharm has provided positive clinical updates across multiple programs.

What is the significance of the B7H3 trial?

The B7H3 trial aims to explore innovative therapeutic options targeting this pathway.

Tags: RADX Viatris Investor Conferences Healthcare RAD AtomVie B7H3 clinical trial Betabart
Last updated: Oct 16, 2024